Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet) vs. Diclofenac (Voltaren) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)

Trial Profile

A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet) vs. Diclofenac (Voltaren) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tramadol/paracetamol (Primary) ; Diclofenac
  • Indications Ankylosing spondylitis; Musculoskeletal pain
  • Focus Therapeutic Use
  • Sponsors Johnson & Johnson

Most Recent Events

  • 28 Apr 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.
  • 06 May 2009 Actual initiation date (Sep 2008) added as reported by ClinicalTrials.gov.
  • 06 May 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top